NEWSROOM

PRESS RELEASES

November 2, 2022
Aristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs Progress

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the appointments of three experienced drug development experts to key positions as it works to progress and expand its clinical pipeline: Himanshu Patel, D.O., as Executive Medical Director, Jennifer Barnes, Ph.D., as Senior Director, Clinical Science, and Walter Frank Eng, PharmD, as Associate Director, Clinical Science. read more →

August 30, 2022
Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS), a chronic and progressive inflammatory dermatological condition. read more →

IN THE NEWS

BioSpace (Alex Keown)

November 4, 2022
Movers & Shakers

San Diego-based Aristea bolstered its clinical operations team with three appointments. Himanshu Patel was named executive medical director; Jennifer Barnes was named senior director of clinical science; and Walter Frank Eng was named associate director of clinical science. read more →

Fierce Biotech (Max Bayer, Gabrielle Masson)

November 4, 2022
Chutes & Ladders

Immunology company Aristea Therapeutics has appointed three new leaders in positions that will guide drug development. read more →

PRESENTATIONS